Elevated CSF and plasma microparticles in a rat model of streptozotocin-induced cognitive impairment

Behavioural Brain Research

Volumn 256, Issue , 2013, Pages 503-511

  Hosseinzadeh, Soheila ^a   Zahmatkesh, Maryam ^a   Zarrindast, Mohammad Reza ^a   Hassanzadeh, Gholam Reza ^a,b   Karimian, Morteza ^a,b   Sarrafnejad, Abdolfattah ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer; Dementia; Membrane derived vesicles

Indexed keywords

BETA3 INTEGRIN; BIOLOGICAL MARKER; LIPOCORTIN 5; MALONALDEHYDE; PROTEIN S100B; STREPTOZOCIN; VASCULAR ENDOTHELIAL CADHERIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENDOTHELIAL MICROPARTICLE; FLOW CYTOMETRY; HIPPOCAMPUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; NONHUMAN; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEROTONIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; TISSUE INJURY;

AD; ALANINE AMINOTRANSFERASE; ALT; ALZHEIMER; ALZHEIMER DISEASE; ASPARTATE AMINOTRANSFERASE; AST; CBC; CEREBROSPINAL FLUID; COMPLETE BLOOD COUNT; CSF; DEMENTIA; EMPS; ENDOTHELIAL-DERIVED MICROPARTICLES; FORWARD SCATTER; FSC; ICV-STZ; INTRACEREBROVENTRICULAR-STREPTOZOTOCIN; MALONDIALDEHYDE; MDA; MEMBRANE-DERIVED VESICLES; MICROPARTICLE; MORRIS WATER MAZE TEST; MP; MWM; PFP; PLATELET-DERIVED MICROPARTICLES; PLATELET-FREE PLASMA; PLATELET-POOR PLASMA; PMPS; PPP; RBC; RED BLOOD CELL; SIDE SCATTER; SSC; WBC; WHITE BLOOD CELL;

ANIMALS; ANNEXIN A5; ANTIGENS, CD; BEHAVIOR, ANIMAL; CADHERINS; CELL-DERIVED MICROPARTICLES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INTEGRIN BETA3; MALE; MALONDIALDEHYDE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, WISTAR; SEROTONIN; STREPTOZOCIN;

EID: 84884402280     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.09.019     Document Type: Article

References (69)

1. Ciabattoni G., Porreca E., Febbo C.D., Iorio A.D., Paganelli R., Bucciarelli T., et al. Determinants of platelet activation in Alzheimer's disease. Neurobiology of Aging 2007, 28:336-342.
2. Agostinho P., Cunha R.A., Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Current Pharmaceutical Design 2010, 16(25):2766-2778.
3. Javed H., Khan M.M., Ahmad A., Vaibhav K., Ahmad M.E., Khan A., et al. Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type. Neuroscience 2012, 210:340-352.
4. Freyssinet J.M. Cellular microparticles: what are they bad or good for?. Journal of Thrombosis and Haemostasis 2003, 1:1655-1662.
5. Doeuvre L., Plawinski L., Toti F., Angles-Cano E. Cell-derived microparticles: a new challenge in neuroscience. Journal of Neurochemistry 2009, 110:457-468.
6. Shet A.S. Characterizing blood microparticles: technical aspects and challenges. Vascular Health and Risk Management 2008, 4(4):769-774.
7. Tual-Chalot S., Guibert Ch Muller B., Savineau J.P., Andriantsitohaina R., Martinez M.C. Circulating microparticles from pulmonary hypertensive rats induces endothelial dysfunction. American Journal of Respiratory and Critical Care Medicine 2010, 182:261-268.
8. Lai C.P., Breakefield X.O. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Frontiers in Physiology 2012, 3:228-242.
9. Minagar A., Jy W., Jimenez J.J., Sheremata W.A., Mauro L.M., Mao W.W., et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001, 56:1319-1324.
10. Jy W., Minagar A., Jimenez J.J., Sheremata W.A., Mauro L.M., Horstman L.L., et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Frontiers in Bioscience 2004, 9:3137-3144.
11. Sheremata W.A., Jy W., Horstman L.L., Ahn Y.S., Alexander J.S., Minagar A. Evidence of platelet activation in multiple sclerosis. Journal of Neuroinflammation 2008, 5:27-32.
12. Cherian P., Hankey G.J., Eikelboom J.W., Thom J., Baker R.I., McQuillan A., et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003, 34:2132-2137.
13. Simak J., Gelderman M.P., Yu H., Wright V., Baird A.E. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. Journal of Thrombosis and Haemostasis 2006, 4:1296-1302.
14. Pawelczyk M., Baj Z., Chmielewski H., Kaczorowska B., Klimek A. The influence of hyperlipidemia on platelet activity markers in patients after ischemic stroke. Cerebrovascular Diseases 2009, 27(2):131-137.
15. Morel N., Morel O., Petit L., Hugel B., Cochard J.F., Freyssinet J.M., et al. Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. Journal of Trauma 2008, 64:698-704.
16. Sabatier F., Roux V., Anfosso F., Camoin L., Sampol J., Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002, 99(11):3962-3970.
17. Horstman L.L., Jy W., Jimenez J.J., Ahn Y.S. Endothelial microparticles as markers of endothelial dysfunction. Frontiers in Bioscience 2004, 9:1118-1135.
18. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. Journal of Neuroinflammation 2011, 8:26-38.
19. Sevush S., Jy W., Horstman L.L., Mao W.W., Kolodny L., Ahn Y.S. Platelet activation in Alzheimer disease. Archives of Neurology 1998, 55:530-536.
20. Xue S., Cai X., Li W., Zhang Z., Dong W., Hui G. Elevated plasma endothelial microparticles in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2012, 34:174-180.
21. Gelderman M.P., Simak J. Flow cytometric analysis of cell membrane microparticles. Methods in Molecular Biology 2008, 484:79-93.
22. Lannert H., Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behavioral Neuroscience 1998, 112(5):1199-1208.
23. Duelli R., Schrock H., Kuschinsky W., Hoyer S. Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. International Journal of Developmental Neuroscience 1994, 12(8):737-743.
24. Tota S., Kamat P.K., Saxena G., Hanif K., Najmi A.K., Nath C. Central angiotensin converting enzyme facilitates memory impairment in intracerebroventricular streptozotocin treated rats. Behavioural Brain Research 2012, 226(1):317-330.
25. Plaschke K., Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. International Journal of Developmental Neuroscience 1993, 11(4):477-483.
26. Sharma M., Gupta Y.K. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sciences 2001, 68:1021-1029.
27. Ishrat T., Khan M.B., Hoda M.N., Yousuf S., Ahmad M., Ansari M.A., et al. Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behavioural Brain Research 2006, 171(1):9-16.
28. Labak M., Foniok T., Kirk D., Rushforth D., Tomanek B., Jasiński A., et al. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease. Acta Neurochirurgica Supplementum 2010, 106:177-181.
29. Morris R. Developments of a water maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 1984, 11:47-60.
30. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clinica Chimica Acta 1978, 90:37-43.
31. Carson F.L. Histotechnology: A Self-Instructional Text 1990, 1-170. ASCP Press, Chicago.
32. Ohkawa R., Hirowatari Y., Nakamura K., Ohkubo S., Ikeda H., Okada M., et al. Platelet release of beta-thromboglobulin and platelet factor 4 and serotonin in plasma samples. Clinical Biochemistry 2005, 38(11):1023-1026.
33. Rothermundt M., Peters M., Prehn J.H., Arolt V. S100B in brain damage and neurodegeneration. Microscopy Research and Technique 2003, 60(6):614-632.
34. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, Sydney.
35. Nirogi R., Kandikere V., Mudigonda K., Bhyrapuneni G., Muddana N., Saralaya R., et al. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. Journal of Neuroscience Methods 2009, 178:116-119.
36. Dachary-Prigent J., Freyssinet J.M., Pasquet J.M., Carron J.C., Nurden A.T. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups. Blood 1993, 81:2554-2565.
37. Trummer A., De Rop C., Tiede A., Ganser A., Eisert R. Isotype controls in phenotyping and quantification of microparticles: a major source of error and how to evade it. Thrombosis Research 2008, 122:691-700.
38. Brown R.E., Corey S.C., Moore A.K. Differences in measures of exploration and fear in MHC-congenic C57BL/6J and B6-H-2K mice. Behavioural Genetics 1999, 29(4):263-271.
39. Garcia S., Chirinos J., Jimenez J., Del Carpio Muñoz F., Canoniero M., Jy W., et al. Phenotypic assessment of endothelial microparticles in patients with heart failure and after heart transplantation: switch from cell activation to apoptosis. Journal of Heart and Lung Transplantation 2005, 24(12):2184-2189.
40. Daniel L., Fakhouri F., Joly D., Mouthon L., Nusbaum P., Grunfeld J.P., et al. Increase of circulating neutrophil and platelet microparticles during acute vasculitis and hemodialysis. Kidney International 2006, 69(8):1416-1423.
41. Boulanger C.M., Amabile N., Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006, 48(2):180-186.
42. Dey-Hazra E., Hertel B., Kirsch T., Woywodt A., Lovric S., Haller H., et al. Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vascular Health and Risk Management 2010, 6:1125-1133.
43. Beyer C., Pisetsky D.S. The role of microparticles in the pathogenesis of rheumatic diseases. Nature Reviews Rheumatology 2010, 6(1):21-29.
44. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Multiple Sclerosis Journal 2003, 9:540-549.
45. Lee Y.L., Jy W., Horstman L.L., Janania J., Reyes Y., Kelley R.E., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thrombosis Research 1993, 72:295-304.
46. Geiser T., Sturzenegger M., Genewein U., Haeberli A., Beer J.H. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998, 29(9):1770-1777.
47. Combes V., Taylor T.E., Juhan-Vague I., Mege J.L., Mwenechanya J., Tembo M., et al. Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. Journal of the American Medical Association 2004, 291(21):2542-2544.
48. Burger D., Schock S., Thompson C.S., Montezano A.C., Hakim A.M., Touyz R.M. Microparticles: biomarkers and beyond. Clinical Science 2013, 124:423-441.
49. Bianco F., Pravettoni E., Colombo A., Schenk U., Möller T., Matteoli M., et al. Astrocyte-derived ATP induces vesicle shedding and IL-1β release from microglia. Journal of Immunology 2005, 174:7268-7277.
50. Baumgarth N., Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. Journal of Immunological Methods 2000, 243:77-97.
51. Burger D., Montezano A.C., Nishigaki N., He Y., Carter A., Touyz R.M. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arteriosclerosis, Thrombosis, and Vascular Biology 2011, 31:1898-1907.
52. Yang C., Mwaikambo B.R., Zhu T., Gagnon C., Lafleur J., Seshadri S., et al. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. American Journal of Physiology - Regulatory Integrative and Comparative Physiology 2008, 294:467-476.
53. Mostefai H.A., Agouni A., Carusio N., Mastronardi M.L., Heymes C., Henrion D., et al. Phosphatidylinositol 3-kinase and xanthine oxidase regulate nitric oxide and reactive oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. Journal of Immunology 2008, 180:5028-5035.
54. Brodsky S.V., Zhang F., Nasjletti A., Goligorsky M.S. Endothelium-derived microparticles impair endothelial function in vitro. American Journal of Physiology. Heart and Circulatory Physiology 2004, 286:1910-1915.
55. Burger D., Kwart D.G., Montezano A.C., Read N.C., Kennedy C.R.J., Thompson C.S., et al. Microparticles induce cell cycle arrest through redox-sensitive processes in endothelial cells: implications in vascular senescence. Journal of the American Heart Association 2012, 1:e001842.
56. Mercado C.P., Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Molecular Interventions 2010, 10(4):231-241.
57. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid β-peptide in human blood. Biochemical and Biophysical Research Communications 1995, 213(1):96-103.
58. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H., et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. American Journal of Pathology 2002, 161(5):1869-1879.
59. Sharples R.A., Vella L.J., Nisbet R.M., Naylor R., Perez K., Barnham K.J., et al. Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB Journal 2008, 22(5):1469-1478.
60. Chaves M.L., Camozzato A.L., Ferreira E.D., Piazenski I., Kochhann R., Dall'Igna O., et al. Serum levels of S100B and NSE proteins in Alzheimer's disease patients. Journal of Neuroinflammation 2010, 7:6-13.
61. Vicente E., Degerone D., Bohn L., Scornavaca F., Pimentel A., Leite M.C., et al. Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Research 2009, 1251:204-212.
62. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathology 1998, 8(1):65-72.
63. Peskind E.R., Griffin W.S., Akama K.T., Raskind M.A., Van Eldik L.J. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochemistry International 2001, 39(5-6):409-413.
64. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. International Journal of Biochemistry and Cell Biology 2001, 33(7):637-668.
65. Van Eldik L.J., Wainwright M.S. The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restorative Neurology and Neuroscience 2003, 21(3-4):97-108.
66. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., et al. S100B's double life: intracellular regulator and extracellular signal. Biochimica et Biophysica Acta 2009, 1793(6):1008-1022.
67. Putz U., Howitt J., Lackovic J., Foot N., Kumar S., Silke J., et al. Nedd4 family-interacting protein 1 (Ndfip1) is required for the exosomal secretion of Nedd4 family proteins. Journal of Biological Chemistry 2008, 283:32621-32627.
68. Hardy J., Revesz T. The spread of neurodegenerative disease. New England Journal of Medicine 2012, 366:2126-2128.
69. Barry O.P., Pratico D., Lawson J.A., FitzGerald G.A. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. Journal of Clinical Investigation 1997, 99(9):2118-2127.